GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Apollomics Inc (NAS:APLMW) » Definitions » Tax Provision

Apollomics (Apollomics) Tax Provision : $-0.01 Mil (TTM As of Dec. 2023)


View and export this data going back to 2023. Start your Free Trial

What is Apollomics Tax Provision?

Apollomics's tax provision for the six months ended in Dec. 2023 was $0.00 Mil. Its tax provision for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.01 Mil.


Apollomics Tax Provision Historical Data

The historical data trend for Apollomics's Tax Provision can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Apollomics Tax Provision Chart

Apollomics Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Tax Provision
0.09 - - -0.01

Apollomics Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Tax Provision Get a 7-Day Free Trial - - - -0.01 -

Apollomics Tax Provision Calculation

Tax to be paid.

Tax Provision for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-0.01 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Apollomics (Apollomics) Business Description

Traded in Other Exchanges
Address
989 East Hillsdale Boulevard, Suite 220, Foster, CA, USA, 94404
Apollomics Inc is an innovative clinical-stage biotechnology company. It is is focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. It has a pipeline of 9 drug candidates across multiple programs, 6 of which are in the clinical stage of development.